RT Journal Article
SR Electronic
T1 Adult multisystem inflammatory syndrome in a patient who recovered from COVID-19 postvaccination
JF BMJ Case Reports
JO BMJ Case Reports
FD BMJ Publishing Group Ltd
SP e242060
DO 10.1136/bcr-2021-242060
VO 14
IS 4
A1 Uwaydah, Ahmad Kanaan
A1 Hassan, Nidal M M
A1 Abu Ghoush, Mousa Suhail
A1 Shahin, Karim Mohamed Mohamed
YR 2021
UL http://casereports.bmj.com/content/14/4/e242060.abstract
AB Multisystem inflammatory syndrome in children has become a recognised syndrome, whereas a parallel syndrome in adults, multisystem inflammatory syndrome in adults (MIS-A), has not been well defined. Most cases occur several weeks following confirmed or suspected SARS-CoV-2 infection, but none have been reported in association with SARS-CoV-2 vaccines. Here we describe the case of a 22-year-old man, who received the inactivated SARS-CoV-2 vaccine 6 weeks following a mild COVID-19 infection. He presented after his second dose of the vaccine with a clinical picture of a multisystem inflammatory syndrome-like illness. Additionally, there was laboratory evidence of acute inflammation. The patient’s condition markedly improved after initiation of steroids. Whether the vaccine augmented an already-primed immunity from the infection and contributed to the occurrence of MIS-A is difficult to prove. Understanding the pathogenesis of this condition will shed light on this question and entail major implications on treatment and prevention.